| | A prospective, open-label, interventional phase IV study to assess the safety of EupentaTM Inj. {fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [r . . . |
Completed |
20 Aug 2021 |
| | A prospective, Phase I, randomized, controlled, open label study to assess the reactogenicity, safety and immunogenicity of a combined liquid DTwP-rHepB-Hib-IPV vaccine when administered to healthy ch . . . |
Completed |
02 Aug 2019 |
| | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient . . . |
Completed |
28 Dec 2021 |
| | A prospective, randomized, open-label, comparative study to assess the efficacy, safety and tolerability of aztreonam-avibactam (ATM-AVI) and best availability therapy for the treatment of serious inf . . . |
Completed |
16 May 2023 |
| | A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events |
Ongoing |
30 Nov -0001 |
| | A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) caus . . . |
Completed |
06 Mar 2023 |
| | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular . . . |
Terminated |
03 Feb 2022 |
| | A randomized double-masked, phase III study assessing ranibizumab intravitreal injections versus sham control in patients with visual impairment due to macular edema (ME) secondary to branch retinal v . . . |
Completed |
25 Jan 2022 |
| | A randomized double-masked, phase III study assessing ranibizumab intravitreal injections versus sham control in patients with visual impairment due to macular edema (ME) secondary to central retinal . . . |
Completed |
25 Jan 2022 |
| | A randomized, blinded, two-part, Phase II trial to evaluate the safety and immunogenicity of the recombinant two-component COVID-19 vaccine (CHO cell) in adults 18 years and older . . . |
Completed |
16 May 2023 |
| | A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephr . . . |
Completed |
02 Mar 2020 |
| | A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis . . . |
Completed |
22 Mar 2022 |
| | A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabe . . . |
Completed |
23 Sep 2019 |
| | A Randomized, Double-Blind, International Multi-Center Clinical Study to Investigate Efficacy and Safety of Lianhua Qingwen Capsules Compared to Placebo and Combined with Standard of Care (SOC) in Adu . . . |
Completed |
23 Feb 2023 |
| | A Randomized, Double-Blind, International Multi-Center Clinical Study to Investigate Efficacy and Safety of Lianhua Qingwen Capsules Compared to Placebo and Combined with Standard of Care (SOC) in Adu . . . |
Ongoing |
30 Nov -0001 |
| | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients wi . . . |
Ongoing |
03 Jul 2020 |
| | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient . . . |
Ongoing |
30 Mar 2021 |
| | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient . . . |
Ongoing |
31 Mar 2021 |
| | A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturn . . . |
Terminated |
04 Jan 2023 |
| | A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARSCoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Yea . . . |
Ongoing |
10 Mar 2023 |
| | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects with Guillain Barré Syndrome (GBS) . . . |
Ongoing |
23 Mar 2022 |
| | A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety, Immunogenicity and Preliminary Efficacy of Multiple Ascending Doses of PIKA Recombinant Protein COVID-19 V . . . |
Terminated |
07 Mar 2023 |
| | A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of MLC1501 in Patients with Stroke (MAESTOSO) . . . |
Ongoing |
02 Feb 2023 |
| | A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease . . . |
Pending |
30 Nov -0001 |
| | A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in Asian subjects (≥16 to 80 years of age) with parti . . . |
Ongoing |
01 Apr 2022 |